Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: Toxicity and matched case comparison with postoperative prostate bed-only radiotherapy - Abstract

PURPOSE: To report on toxicity of postoperative high-dose whole-pelvis radiotherapy (WPRT) with androgen deprivation therapy for lymph node metastasized (N1) prostate cancer (PC).

To perform a matched-case analysis to compare this toxicity profile to postoperative prostate bed-only radiotherapy (PBRT).

MATERIALS AND METHODS: Forty-eight N1-PC patients were referred for WPRT and 239 node-negative patients for PBRT. Patients were matched 1:1 according to pre-treatment demographics, symptoms, treatment and tumor characteristics. Mean dose to the prostate bed was 75Gy (WPRT-PBRT) and 54Gy to the elective nodes (WPRT) in 36 or 37 fractions. End points are genito-urinary (GU) and gastro-intestinal (GI) toxicity.

RESULTS: After WPRT, 35% developed grade 2 (G2) and 4% G3 acute GU toxicity. Acute GI toxicity developed in 42% (G2). Late GU toxicity developed in 36% (G2) and 7% (G3). One patient had G4 incontinence. Recuperation occurred in 59%. Late GI toxicity developed in 25% (G2) with 100% recuperation. Incidence of acute and late GI toxicity was higher following WPRT compared to PBRT (p⩽ 0.041). GU toxicity was similar. With WPRT mean dose to bladder and rectosigmoid were higher.

CONCLUSIONS: Postoperative high-dose WPRT comes at the cost of a temporary increase in G2. GI toxicity compared to PBRT because larger volumes of rectosigmoid are irradiated.

Written by:
Van Praet C, Ost P, Lumen N, De Meerleer G, Vandecasteele K, Villeirs G, Decaestecker K, Fonteyne V.   Are you the author?
Department of Urology, Ghent University Hospital, Belgium.

Reference: Radiother Oncol. 2013 Sep 6. pii: S0167-8140(13)00410-6.
doi: 10.1016/j.radonc.2013.08.021


PubMed Abstract
PMID: 24016674

UroToday.com Prostate Cancer Section